Healthcare entity
The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window. Of the tracked stories, 1 of 3 also mention Donald Trump, the most common co-covered peer.
Last mentioned: 4d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window. Of the tracked stories, 1 of 3 also mention Donald Trump, the most common co-covered peer. Across a 163-day span, the pace is roughly 0.1 stories per week. The 6.7 average consequence score is above the beat benchmark of 6 in the same window. We currently track 3 Healthcare stories that mention STAT News, published between March 10, 2026 and August 19, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 885 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering STAT News. Shared-story counts are live from our verified record — not editorial picks.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
Hartford Courant reports Trump picks Overton
The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
80-week trial results released
Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.
Reports that Dr. Heidi Overton will be nominated to lead FDA introduce new regulatory uncertainty for health IT vendors, medical device manufacturers, and digital health companies. As a White House adviser without a public FDA track record, her stance on software-as-a-medical-device, telehealth, and AI-enabled diagnostics is unclear. Health technology leaders should monitor confirmation and early policy signals.
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
A new analysis reveals a 35% decline in antimicrobial R&D among the world's largest pharmaceutical companies over the last five years. This retreat highlights a deepening crisis in the antibiotic market, where low returns on investment are driving major players toward more lucrative therapeutic areas.
STAT News is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
